Patients with hepatitis C virus (HCV) are often not evaluated thoroughly for depression during routine clinical interviews, possibly compromising clinical trials for drugs and therapies for treating patients with HCV.
Neuroscience researchers suggest that utilizing fMRI studies could help to provide biomarkers for the diagnosis of depression. A recent fMRI study of patients with depression showed marked abnormal activations in the medial prefronal cortex. Researchers believe that by identifying the neurobiological markers for depression, psychiatrists can tailor medications and therapies to suit the needs of individual patients.
After inserting a gene into mice that increases choline transporter and as a result increases acetylcholine at the neuromuscular junctions, the engineered mice were able to run on treadmills twice as long as controls without the inserted gene.